Trial Data Show Extended Benefit With Inebilizumab in Myasthenia Gravis

(MedPage Today) — Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was presented at the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting…

Source link : https://www.medpagetoday.com/meetingcoverage/aanemvideopearls/118277

Author :

Publish date : 2025-11-03 17:21:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Trial Data Show Extended Benefit With Inebilizumab in Myasthenia Gravis

Walking 3000 steps a day seems to slow Alzheimer’s-related decline

UK Regulator Targets Delays in Rare Disease Treatments

Related Posts

Supplement Yanked Over Suicide Risk; ‘Dilbert’ Creator Dies; Full-Body Scan Lawsuit

More People Survive Cancer, Report Shows

Are Cardiologists Overlooking Substance Use Risk?

‘It’s life-changing. I can see my child grow up’

Sleeping With the Light on May Increase Heart Disease Risk

What Do the New VCID Guidelines Mean for Clinical Practice?

Supplement Yanked Over Suicide Risk; ‘Dilbert’ Creator Dies; Full-Body Scan Lawsuit

More People Survive Cancer, Report Shows

Are Cardiologists Overlooking Substance Use Risk?

‘It’s life-changing. I can see my child grow up’

Sleeping With the Light on May Increase Heart Disease Risk

What Do the New VCID Guidelines Mean for Clinical Practice?

Could AI Help Predict the Next Pandemic?

We must completely change the way we build homes to stay below 2°C

Categories

Archives